The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer

Clinical Lung Cancer

Volumn 11, Issue 2, 2010, Pages 82-90

  Langer, Corey ^a   Soria, Jean Charles ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Angiogenesis; Bevacizumab; Cetuximab; Combination therapy; Erlotinib; Tyrosine kinase inhibitors

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; BEVACIZUMAB; BMS 690514; CARBOPLATIN; CEDIRANIB; CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PEMETREXED; PF 299804; PLACEBO; SOMATOMEDIN C RECEPTOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; XL 647;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; ENDOTHELIUM CELL; HUMAN; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 77952472159     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.011     Document Type: Review

References (81)

1. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550
2. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated nonsmall- cell lung cancer. N Engl J Med 2005; 353:123-132
3. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006; 24:3831-3837
4. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-1537
5. Pirker R, Szczesna A, Von Pawel J, et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26(suppl):6s (abstract 3).
6. Bozec A, Fischel JL, Milano G. Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience. Curr Opin Oncol 2006; 18:330-334
7. Wu W, Onn A, Isobe T, et al. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 2007; 6:471-483
8. Buck E, Eyzaguirre A, Brown E, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006; 5:2676-2684
9. Di Cosimo S, Matar P, Rojo F, et al. The mTOR pathway inhibitor RAD001 induces activation of AKT which is completely abolished by gefitinib, an anti- EGFR tyrosine kinase inhibitor, and combined sequence specific treatment results in greater antitumor activity. Proc Am Assoc Cancer Res 2004; 45:1233.
10. Di Cosimo S, Matar P, Rojo F, et al. Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001). J Clin Oncol 2004; 22(suppl):213s (abstract 3074).
11. Morgillo F, Lee HY. Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist Updat 2005; 8:298-310.
12. Farace F, Massard C, Borghi E, et al. Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells. Ann Oncol 2007; 18:1421-1422
13. O'Hanlon LH. Taking down tumors: vascular disrupting agents entering clinical trials. J Natl Cancer Inst 2005; 97:1244-1245
14. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-1508
15. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the antivascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23:2544-2555
16. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007; 25:4743-4750
17. Gridelli C, Maione P, Rossi A. The potential role of mTOR inhibitors in nonsmall cell lung cancer. Oncologist 2008; 13:139-147
18. Papadimitrakopoulou V, Blumenschein G, Leighl NB, et al. A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): phase 1 results. J Clin Oncol 2008; 26(suppl):436s (abstract 8051).
19. Johnson BE, Jackman D, Janne PA. Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. Clin Cancer Res 2007; 13:s4628-31.
20. Clinicaltrials.gov [Web site]. Combination study of CP-751,871 with paclitaxel and carboplatin in advanced lung cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00147537. Accessed: October 6, 2008.
21. Clinicaltrials.gov [Web site]. A study to assess the effectiveness of the combination of carboplatin, pacliatxel, bevacizumab and combretastatin (CA4P) in patients with chemotherapy naive lung cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00653939. Accessed: October 6 2008.
22. Rowinsky EK, Youssoufian H, Tonra JR, et al. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007; 13:5549s-55s.
23. Clinicaltrials.gov [Web site]. A study to evaluate the efficacy of bevacizumab in combination with Tarceva for advanced non-small cell lung cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00130728. Accessed: October 6, 2008.
24. Clinicaltrials.gov [Web site]. A study comparing bevacizumab therapy with or without erlotinib for first-line treatment of non-small cell lung cancer (ATLAS). Available at: http://www.clinicaltrials.gov/ct/show/NCT00257608. Accessed: October 6, 2008.
25. Clinicaltrials.gov [Web site]. Trial of CP-751, 871 and erlotinib in refractory lung cancer (NSCLC). Available at: http://clinicaltrials.gov/ct2/ show/NCT00673049.Accessed: October 6, 2008.
26. Cross MJ, Dixelius J, Matsumoto T, et al. VEGF-receptor signal transduction. Trends Biochem Sci 2003; 28:488-494
27. Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006; 7:359-371
28. Ellis LM. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am 2004; 18:1007-1021
29. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007; 5:203-220
30. De Luca A, Carotenuto A, Rachiglio A, et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008; 214:559-567
31. Sandler A, Herbst R. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 2006; 12:4421s-5s.
32. Byers LA, Heymach JV. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. Clin Lung Cancer 2007; 8(suppl):S79-85.
33. Gandara DR, Davies AM, Gautschi O, et al. Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. Clin Lung Cancer 2007; 8(suppl):S61-7.
34. Davies AM, Ho C, Lara PN, Jr, et al. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-smallcell lung cancer. Clin Lung Cancer 2006; 7:385-388
35. Kaelin WG, Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5:689-698
36. Cascone T, Gridelli C, Ciardiello F. Combined targeted therapies in non-small cell lung cancer: a winner strategy? Curr Opin Oncol 2007; 19:98-102.
37. Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti- VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3:24-40.
38. Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 2007; 8:15-27.
39. Sandler A. Bevacizumab in non small cell lung cancer. Clin Cancer Res 2007; 13:s4613-6.
40. Clinicaltrials.gov [Web site]. A study of aflibercept versus placebo in patients with second-line docetaxel for locally advanced or metastatic non-small-cell lung cancer (VITAL). Available at: http://www.clinicaltrials.gov/ ct2/show/NCT00532155.Accessed: October 6, 2008.
41. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009; 27:1227-1234
42. Manegold C, von Pawel J, Zatloukal P, et al. BO17704 (AVAIL): a phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent non-squamous, non-small cell lung cancer (NSCLC). Ann Oncol 2008; 19(suppl 8):viii1. Abstract LBA1.
43. Gasparini G, Longo R, Fanelli M, et al. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 2005; 23:1295-1311
44. Keedy VL, Sandler AB. Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Sci 2007; 98:1825-1830
45. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184-2191
46. Hirsch FR, Varella-Garcia M, Bunn PA, Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21:3798-3807
47. Lynch TJ, Adjei AA, Bunn PA, Jr, et al. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res 2006; 12:4365s-71s.
48. Dancey JE. Epidermal growth factor receptor inhibitors in non-small cell lung cancer. Drugs 2007; 67:1125-1138
49. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892-5899
50. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25:1545-1552
51. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372:1809-1818
52. Mok T, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957
53. ImClone Systems Incorporated [Web site]. Erbitux phase 3 BMS-099 lung cancer study secondary endpoint: overall survival results announced. Available at: http://phx.corporate-ir.net/phoenix.zhtml?c=97689&p= irolnewsArticle&ID=1192099&highlight=. Accessed: October 6 2008.
54. Groen HJ, Smit EF, Dingemans A. A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(suppl):415s Abstract 7625.
55. Clinicaltrials.gov [Web site]. Study of bevacizumab and erlotinib in patients with advanced non-small cell lung cancer (NSCLC). Available at: http://clinicaltrials.gov/ct2/show/NCT00553800. Accessed: October 6, 2008.
56. Hainsworth J, Herbst R. A phase III, multicenter, placebo-controlled, doubleblind, randomized clinical trial to evaluate the efficacy of bevacizumab (Avastin) with erlotinib (Tarceva) compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy. J Thorac Oncol 2008; 3(suppl 4):S302 Plenary abstract.
57. Miller VA, O'Connor P, Soh C, et al. A randomized, double-blind, placebocontrolled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27(suppl):799s. (abstract LBA8002).
58. Flaherty KT. Sorafenib: delivering a targeted drug to the right targets. Expert Rev Anticancer Ther 2007; 7:617-626
59. de La Motte RT, Galluzzi L, Olaussen KA, et al. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 2007; 67:6253-6262
60. Bahleda R, Felip E, Herbst R, et al. Phase I multicenter trial of BMS-690514: safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors and non-small cell lung cancer. J Clin Oncol 2008; 26(suppl):128s (abstract 2564).
61. Einhorn LH, Bonomi P, Bunn PA, Jr, et al. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. J Thorac Oncol 2008; 3:545-555
62. Natale RB, Bodkin D, Govindan R, et al. ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized phase II trial. J Clin Oncol 2006; 24(18S):364s (abstract 7000).
63. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26:650-656
64. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007; 25:4270-4277
65. Schiller JH, Lee JW, Hanna NH, et al. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J Clin Oncol 2008; 26(15S): (Abstract 8014).
66. Bayer HealthCare Pharmaceuticals [Web site]. Bayer and Onyx provide update on phase 3 trial of Nexavar in patients with non-small cell lung cancer. Available at: http://www.pharma.bayer.com/scripts/pages/en/news-room/ news-room/news-room50.php. Accessed: October 6, 2008.
67. Scagliotti G, von Pawel J, Reck M, et al. Sorafenib plus carboplatin/paclitaxel in chemonaive patients with stage IIIB-IV non-small cell lung cancer (NSCLC): interim analysis (IA) results from the phase III, randomized, double-blind, placebo-controlled, ESCAPE (Evaluation of Sorafenib, Carboplatin, and Paclitaxel Efficacy in NSCLC) trial. J Thorac Oncol 2008; 3(suppl):S97 (abstract 275O).
68. AstraZeneca [Web site]. AstraZeneca provides update on Recentin clinical development programme. Available at: http://www.astrazeneca.com/pressrelease/ 5377.aspx. Accessed: October 6, 2008.
69. Clinicaltrials.gov [Web site]. Cediranib, paclitaxel, and carboplatin in treating patients with stage IIIB or stage IV non-small cell lung cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00795340. Accessed: July 30, 2009.
70. AstraZeneca [Web site]. AstraZeneca completes enrollment in two pivotal phase III studies of the investigational drug vandetanib (Zactima) in nonsmall cell lung cancer (NSCLC). Available at: http://www.astrazeneca-us.com/search/? itemId=2324535. Accessed October 6, 2008.
71. Clinicaltrials.gov [Web site]. ZD6474 (Zactima) phase III study in EGFR failures. Available at: http://clinicaltrials.gov/ct2/show/NCT00404924. Accessed: July 30, 2009.
72. Natale R, Thongprasert S, Greco FA, et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). J Clin Oncol 2009; 27(suppl):409s (abstract 8009).
73. De Boer R, Arrieta Ó, Gottfried M, et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL). J Clin Oncol 2009; 27(suppl):409s (abstract 8010).
74. Herbst RS, Sun Y, Korfee S, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). J Clin Oncol 2009; 27(suppl):407s (abstract CRA8003).
75. Ho C, Davies A, Mack P, et al. Dual inhibition: combining epidermal growth factortargeted therapies in non-small-cell lung cancer. Clin Lung Cancer 2007; 8:420-424
76. Ramalingam S, Forster J, Naret C, et al. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. J Thorac Oncol 2008; 3:258-264
77. Marinov M, Fischer B, Arcaro A. Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol 2007; 63:172-182
78. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007; 6:1-12.
79. Karp D, Paz-Ares L, Novello S, et al. High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC. J Clin Oncol 2008; 26(suppl):427s (abstract 8015).
80. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7:504-516
81. Kelland L. Targeting established tumor vasculature: a novel approach to cancer treatment. Curr Cancer Ther Rev 2005; 1:1-9.